Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2024

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2031

Conditions

Chronic Kidney Diseases

Interventions

DRUG

Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)

Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)

Trial Locations (1)

RECRUITING

Mayo Clinic, Jacksonville